Blog - Page 4139 of 5482

MondayNov 03, 2008 7:18 am

Inter-Atlantic Financial, Inc. (AMEX: IAN)

Inter-Atlantic Financial, Inc. (AMEX: IAN) is a newly organized blank check company formed for the purpose of acquiring, through a merger, a capital stock exchange, asset acquisition, stock purchase or other similar business combination, an unidentified domestic and/or foreign operating business in the financial services industry or businesses deriving a majority of their revenues from providing services to financial services companies, including for example, payment processing companies and technology providers. For further information, visit the company website at: www.interatlantic.com.

MondayNov 03, 2008 7:17 am

InterAmerican Acquisition Group Inc. (OTC BB: IAQG)

InterAmerican Acquisition Group Inc. (OTC BB: IAQG) is a blank check company recently formed for the purpose of acquiring, through a merger, stock exchange, asset acquisition or other similar business combination, an unidentified operating business. The company specializes in Project Management, Project Financing and Investment Banking. Recently, the company made news by raising $46 million. For further information, visit the company website at: www.interamerican-group.com.

MondayNov 03, 2008 7:16 am

Insmed Incorporated (NASDAQ: INSM)

Insmed Incorporated (NASDAQ: INSM), a development stage company, has comprehensive expertise in protein drug development. The company has a state-of-the art FDA-approved biologic commercial manufacturing facility in Boulder, Colorado and a corporate office in Richmond Virginia. By pursuing a dual path strategy, Insmed aims to advance its proprietary protein platform into niche markets with unmet needs while entering into the follow on biologics arena. For further information, visit the Company's web site at www.insmed.com.

MondayNov 03, 2008 7:08 am

InSite Vision Incorporated (AMEX: ISV)

InSite Vision Incorporated (AMEX: ISV) is focused on developing novel ophthalmic products for the treatment of a growing range of common eye problems, including ocular infection, glaucoma, and retinal disease. Their goal as a company is to provide patients and physicians with better treatment options that help preserve and improve vision worldwide. By leveraging their proprietary DuraSite® drug delivery technology, the company is creating alternative ocular anti-infective therapies that may provide substantial advantages over existing treatment options. For further information, visit the Company's web site at www.insite.com.

MondayNov 03, 2008 7:07 am

Inovio Biomedical Corporation (AMEX: INO)

Inovio Biomedical Corporation (AMEX: INO)Inovio Biomedical Corporation (AMEX: INO) has their focus on developing multiple DNA-based immunotherapies. The company is known as a leading developer of human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Inovio's DNA delivery technology has demonstrated the ability to substantially increase gene expression and immune responses from DNA vaccines. For further information, visit the Company's web site at www.inovio.com.

MondayNov 03, 2008 7:07 am

Inhibitex, Inc. (NASDAQ: INHX)

Inhibitex, Inc. (NASDAQ: INHX) is a biopharmaceutical company engaging in the development of differentiated anti-infective products designed to prevent and treat serious infections. The company’s products include FV-100, a nucleoside analogue prodrug; HIV Integrase Inhibitors class of anti-retroviral agents; and a series of nucleoside and non-nucleoside HCV polymerase inhibitors designed to treat the hepatitis C virus. For further information, visit the Company's web site at www.inhibitex.com.

MondayNov 03, 2008 7:06 am

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), an innovative cancer drug discovery and development company, is focused on discovering, developing, and delivering best-in-class medicines designed to treat cancer and related conditions. The company leverages its proven scientific expertise and passion for developing novel small molecule drugs designed to target emerging cancer pathways. Infinity's two most advanced programs are examples of its innovative approach to oncology drug discovery and development. For further information, visit the Company's web site at www.infi.com.

MondayNov 03, 2008 7:05 am

India Globalization Capital, Inc. (AMEX: IGC)

India Globalization Capital, Inc. (AMEX: IGC) is a company that was formed to acquire operating businesses located in India through merger, capital stock exchange, asset acquisition or other similar business combination. India Globalization Capital (IGC) has three main competencies which are: Highway and Heavy Construction, Mining and Quarrying, and Civil Construction and Engineering of high-temperature plants. IGC is a step ahead of their competition because they are the only Indian infrastructure company listed and trading in the United States. For further information, visit the company

MondayNov 03, 2008 7:04 am

Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV)

Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV), a specialty pharmaceutical company, is focused on the acquisition, development, and commercialization of products designed to treat conditions in urology and endocrinology. The company's approved products include SANCTURA® and SANCTURA XR(TM) for overactive bladder, SUPPRELIN® LA for central precocious puberty, VANTAS® for advanced prostate cancer, and DELATESTRYL® to treat male hypogonadism. For further information, visit the Company's web site at www.indevus.com.

MondayNov 03, 2008 7:04 am

ImmunoCellular Therapeutics, Ltd. (OTC BB: IMUC)

ImmunoCellular Therapeutics, Ltd. (OTC BB: IMUC), a clinical-stage company, is focused on developing new therapeutics to fight cancer using the human body’s immune system. Their product pipeline consists of cellular immunotherapies that target brain cancer, and monoclonal antibodies designed to diagnose and treat various cancers. The company’s lead product candidate is currently in a Phase I clinical trial to treat glioblastoma multiforme, the most common type of brain tumor. For further information, visit the Company's web site at www.imuc.com.

Site Search

Company Search